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Abstract
Background: The Drosophila Male Specific Lethal (MSL) complex contains chromatin modifying enzymes and non-
coding roX RNA. It paints the male X at hundreds of bands where it acetylates histone H4 at lysine 16. This epigenetic 
mark increases expression from the single male X chromosome approximately twofold above what gene-specific 
factors produce from each female X chromosome. This equalises X-linked gene expression between the sexes. Previous 
screens for components of dosage compensation relied on a distinctive male-specific lethal phenotype.
Results: Here, we report a new strategy relying upon an unusual male-specific mosaic eye pigmentation phenotype 
produced when the MSL complex acts upon autosomal roX1 transgenes. Screening the second chromosome 
identified at least five loci, two of which are previously described components of the MSL complex. We focused our 
analysis on the modifier alleles of MSL1 and MLE (for 'maleless'). The MSL1 lesions are not simple nulls, but rather alter 
the PEHE domain that recruits the MSL3 chromodomain and MOF ('males absent on first') histone acetyltransferase 
subunits to the complex. These mutants are compromised in their ability to recruit MSL3 and MOF, dosage 
compensate the X, and support long distance spreading from roX1 transgenes. Yet, paradoxically, they were isolated 
because they somehow increase MSL complex activity immediately around roX1 transgenes in combination with wild-
type MSL1 subunits.
Conclusions: We propose that these diverse phenotypes arise from perturbations in assembly of MSL subunits onto 
nascent roX transcripts. This strategy is a promising alternative route for identifying previously unknown components 
of the dosage compensation pathway and novel alleles of known MSL proteins.
Background
Some organisms use a genetic mechanism to specify sex
[1]. This often leads to degeneration of one homologue of
the critical sex-determining chromosome. Consequently,
these species evolve a mechanism to survive the other-
wise lethal consequences of monosomy for a large chro-
mosome in one sex. In Drosophila  the primary
mechanism of dosage compensation is male-specific
hypertranscription of most genes along his single X chro-
mosome to match the RNA output from the two X chro-
mosomes found in females [2-4]. This hypertranscription
is mediated by acetylation of histone H4 at K16 [5-7]
throughout the entire body of transcribed genes hinting
that the underlying mechanism may be an increase in the
elongation rate of RNA polymerase across X-linked genes
[8-11]. The mechanism by which dosage compensation is
limited to males is well understood [12-15], but how X-
linked genes are distinguished from autosomal genes is
only beginning to come into focus [16-19].
Dosage compensation is carried out by a chromatin
remodelling complex composed of large non-coding roX
(for 'RNA on the X chromosome') RNAs and at least five
MSL (for 'male-specific lethal') proteins: MSL1 (scaffold
protein), MSL2 (RING finger protein), MSL3 (chromodo-
main protein), MOF ('males absent on first', histone H4
acetyltransferase) and MLE (for 'maleless', RNA helicase)
[20]. A chromatin remodelling complex consisting of
MSL1, MSL2, MSL3 and MOF is also found in verte-
brates [21,22]. So far no RNA helicase or non-coding
RNA has been linked to the vertebrate MSL complex.
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MSL1 seems particularly important structurally because
it contains docking sites for three of the other subunits. A
predicted coiled coil near N-terminus binds MSL2
[23,24], and a domain near the C-terminus, containing a
PEHE motif, binds MSL3 and MOF [23,25]. The interac-
tions between the C-terminal region of MSL1 with MSL3
and MOF are the focus of this study. Outside these
motifs, most of the sequence is poorly conserved even
within the genus Drosophila. It is not clear how roX
RNAs interact with the protein subunits although non-
sequence-specific RNA interactions have been reported
for MOF, MSL3 and MLE [26-28]. The C-terminal region
of MSL2 is required for efficient roX RNA incorporation
into MSL complexes, but it is not clear if this represents
direct protein-RNA contacts [29]. The MSL complex is
able to spread long distances in cis from sites of roX RNA
synthesis, and this has been taken as evidence that the
MSL protein subunits begin assembling onto nascent roX
transcripts cotranscriptionally [30-33].
The genes encoding the protein components of the
complex were discovered because of their distinctive
male-specific lethal loss of function phenotype. The two
roX  genes were found in screens for sex-specific tran-
scripts and later found to act in dosage compensation
[34,35]. Several groups have studied the biochemical
composition of the dosage compensation complex
searching for additional components. These reports indi-
cate that there are unlikely to be additional roX-like RNA
genes [31], but several proteins copurify with the MSL
complex including components of the nuclear pore
[36,37]. Additionally, general chromatin remodelling pro-
teins such as ISWI, NURF301, JIL-1, HP1, and Su(var)3-7
display complex genetic interactions with the MSL com-
plex [38-43]. However, in each case it is unclear exactly
how the different factors normally interact to produce the
proper chromatin architecture along the male X.
If any component of the dosage compensation pathway
performed additional functions, it may have been over-
looked in screens for male-specific lethal mutants.
Enhancer-suppressor screens have been highly successful
for identifying components of many pathways in flies and
other model organisms, but the sex-specific lethality of
dosage compensation is not easily incorporated into such
a strategy. For instance, an inversion that places the nor-
mally euchromatic white  locus next to centric hetero-
chromatin results in mosaic white expression (mosaic eye
pigmentation) in both sexes. Many dozens of dominant
modifier Su(var) mutants have been isolated that alter the
eye colour of In(1) wM4 flies. These turned out to encode
key chromatin modifying enzymes. Here we report a new
genetic strategy that exploits epigenetic male-specific
mosaic eye colour as a simple phenotypic readout for
local MSL activity amenable to modifier screens. We used
unusual transgenic stocks in which a roX1 transgene had
been inserted in random autosomal sites [44]. Consistent
with earlier findings, the autosomal roX1  transgenes
could support dosage compensation of the X even if they
were the only source of roX RNA [32,34]. The surprising
finding was that while most roX1 autosomal insertions
expressed the adjacent miniwhite marker normally to give
solid pigmented eye colour in both males and females,
roughly 10% to 15% of the random insertions displayed
mosaic patches of eye pigment only in males. Many lines
show further pairing-dependent silencing of miniwhite
where homozygous males have less pigmentation than
hemizygotes. These unusual stocks had the transgene
integrated in a wide variety of sites, and the females in
these stocks had either pale eye colour or completely
white eyes indicating that the miniwhite reporter was epi-
genetically silenced. The miniwhite marker could be acti-
vated in females that were supplied with a complete set of
dosage compensation components showing that eye
colour was a marker for MSL complex activity [44]. In
these stocks, the roX1  gene nucleated ectopic dosage
compensation at the transgene, opening the surrounding
chromatin and permitting miniwhite  expression in
patches in the male eye. When these roX1 transgenes that
have mosaic eye pigmentation were crossed into males
deleted for the endogenous roX1 and roX2 genes, MSL
complex spread > 1 Mbp from the autosomal sites of roX1
transcription in essentially all cells in larval salivary
glands. This was accompanied by a change to solid red
eye colour only in males [32]. This shows that subtle
changes in the local distribution or activity of the MSL
complex can be easily detected by alterations in the epi-
genetic male mosaic eye pattern long before they affect
male viability.
We exploited these unusual transgenics stocks to carry
out a dominant modifier screen searching for mutations
t h a t  a l t e r  M S L  c o m p l e x  a c t i v i t y  e n o u g h  t o  d e t e c t  a
change in male eye colour. In this strategy, all flies retain
one wild-type allele of the candidate modifier gene, so
that if the gene of interest performs essential functions
besides dosage compensation, viable animals are still
recovered. It is possible to search for mutants that either
epigenetically changed from mosaic to solid red (more
MSL activity at the roX1 transgene) or nearly solid white
(less MSL activity). Here, we report the results of the for-
mer screen. Of the 13 mutations isolated, 4 mapped to
known components of the dosage compensation complex
demonstrating the specificity of the screen design. We
focused our analysis on the new mutations in msl1
because they likely alter complex assembly and spreading
by disrupting the interface that binds MSL3 and MOF,
two other well characterised subunits of the dosage com-
pensation complex. The new msl1 alleles display a com-
plex pattern of gain of function and loss of function when
subjected to a battery of assays.Prabhakaran and Kelley BMC Biology 2010, 8:80
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Results
A genetic screen for dominant modifiers of dosage 
compensation
We carried out a dominant F1 enhancer screen (Figure
1a) on a GMroX1  transgene that carries a wild-type
genomic melanogaster roX1 gene on a 4.9 kb EcoRI frag-
ment adjacent to the miniwhite eye pigmentation marker
[45] inserted in a YOYO element at 75C in the euchro-
matic region of the third chromosome. This transgene is
subject to further pairing-dependent silencing in males
(compare Figure 1c, d). Initially we found that reducing
the dose of the known MSL proteins by half in males
heterozygous for msl1, msl2, msl3 and mle had no consis-
tent effect on the mosaic eye pattern of males carrying
one copy of GMroX1-75C  (data not shown). However,
removing the endogenous roX1 and roX2 genes resulted
in sons with solid red eyes and extensive cis spreading of
the MSL complex from the transgene, presumably
because, in the absence of endogenous roX expression,
more MSL subunits are available to associate with the
roX1 transcripts made at the transgene (Park et al. [32]
and Figure 1c).
Figure 1 Modifiers of dosage compensation. (a) From approximately 10,000 G1 sons screened, 13 modifier lines were established. (b) The muta-
tions were placed in complementation groups by assaying for recessive lethality. Alleles of groups A and B are indicated by arbitrary isolation numbers 
and are lethal to both males and females. Alleles of msl1 and mle are named by their codon changes where Z = frameshift and X = nonsense codon. 
*The modifiers scored as single hits each carries a recessive lethal mutation, but it is not known whether this maps to the modifier locus or an extra-
neous gene on the same chromosome. (c) The hemizygous GMroX1-75C males displays mosaic pigmentation when the endogenous roX+ genes are 
present and the Male Specific Lethal (MSL) complex binds a single band at 75C. Male eye colour is derepressed and MSL complex spreads > 1 Mb 
when both endogenous roX genes are deleted. (d) All flies are homozygous for GMroX1-75C and heterozygous for the msl1 mutation indicated. The 
top row shows males, the lower two rows are females. The mosaic eyes of GMroX1-75C homozygous males become almost solid red when a modifier 
mutation is present. Mutations P864L, F979Z and S943F are new alleles of msl1 that were isolated in the present study. Df = msl1L60 [46] has no effect 
on the mosaic pattern. AFG and K1009X are previously identified msl1 lesions that map near the modifier mutations, but have little or no effect on the 
mosaic miniwhite expression. Bottom rows: GMroX1-75C females have pure white eyes and this is not affected by any of the modifier mutations. (e) 
Homozygous P864L escaper males display enhanced miniwhite expression. (f) The modifier mutants (msl1P864L shown) have no effect upon In(1) wm4 
whereas Su(var)2-5 is a potent suppressor of position effect variegation (PEV).Prabhakaran and Kelley BMC Biology 2010, 8:80
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We screened approximately 104  ethyl methane sul-
fonate (EMS)-treated sons for mutations that increased
the fraction of red eye tissue and established 13 second
chromosome mutant stocks that transmitted the modifier
mutation through the germline (Figure 1b). While the
modifiers enhanced miniwhite expression in males indi-
cating that the MSL complex is more active immediately
around the roX1 transgene, they were unable to stimulate
miniwhite expression in females (Figure 1d, P864L). The
modifiers also overcame the pairing-dependent repres-
sion so the change in eye phenotype was more dramatic
when the GMroX1-75C  transgene was homozygous.
Mapping and complementation analysis indicated that
three mutations are unusual alleles of msl1 (Figure 1b, d)
and one maps to mle, two critical components of the dos-
age compensation complex.
The enhanced pigmentation we observe with the modi-
fier mutations cannot be due to MSL1 haploinsufficiency,
but rather the modifiers must make proteins with altered
activities. This was shown by testing the L60 deletion [46]
in  msl1L60/+;  GMroX1-75C/GMroX1-75C  males and
observing no effect on the eye pigmentation pattern (Fig-
ure 1d). We recovered essentially equal numbers of
msl1Mod/+ sons compared to either msl1Mod/+ sisters or
+/+ brothers arguing against an antimorphic mechanism
(data not shown). Surprisingly, after extraneous second-
ary mutations were removed by recombination, some
homozygous modifier males were recovered which also
showed solid red eyes (Figure 1e). The solid red eye phe-
notype of modifier males argues that mutants have an
increased probability of modifying the local chromatin
around the roX1 insertion. By contrast, the male specific
lethality observed in modifier/Df animals demonstrates
that the modifiers have reduced ability to dosage com-
pensate the X.
To exclude the possibility that these mutants affected
general silencing, we tested their effects on the well char-
acterised position effect variegation (PEV) mutation In
(1) wm4, which displays mosaic pigmentation in both
sexes. While Su(var)2-5 made the eyes solid red in both
sexes as expected [47], our new modifier mutations had
no effect (Figure 1f). Furthermore, in mosaic lines where
GMroX1 transgene is inserted at the telomere of chromo-
some 2R (60F) or at the 5' end of the defective proventric-
ulus (dve) gene (58D), each of the three modifier msl1
mutations increased red pigmentation in male eyes
(Additional file 1) but the females remained pure white.
These results show that the effect of the modifiers is com-
pletely male specific and largely independent of chroma-
tin context. This indicates that they act on some aspect of
the dosage compensation pathway rather than the sur-
rounding repressive chromatin. This is consistent with
the finding that most mosaic GMroX1 insertions respond
weakly or not at all to suppressor of variegation muta-
tions or dose of the heterochromatic Y chromosome [44].
In the specific case of the GMroX1 insertion at 75C used
for our screen, mutations in Su(var)2-5, Su(var)3-7, and
su(z)12 each failed to make the eyes red (data not shown).
The modifier MSL1 mutations map to the conserved PEHE 
domain
Sequencing showed that the three modifier msl1 muta-
tions fell in the most conserved PEHE domain that binds
MSL3 and MOF (Figure 2a, b and Additional file 2). Two
alleles, P864L and S943F, are missense mutations that
changed amino acid residues conserved within the genus
Drosophila. The third allele, F979Z, is an 11-bp deletion
replacing the last 61 amino acids of MSL1 with 25 amino
acid residues from another reading frame. These residues
are near the previously defined MOF and MSL3 binding
sites (Figure 2c). We tested whether simply disrupting the
PEHE domain would cause the dominant eye pigmenta-
tion effect on mosaic GMroX1 transgenes. In previously
unpublished screens for msl1 mutations, alleles mapping
near the C-terminus were recovered that behaved as nulls
in male viability assays. The msl1AFG allele changes two
nearby codons, 965 and 967, from AFG, a triplet con-
served from flies to mammals, to EFF (Figure 2b and
Additional file 2). The second pre-existing allele, K1009X,
generates a stop codon soon after the PEHE domain trun-
cating the last 31 residues. Neither the AFG nor K1009X
mutations behaved as modifiers, although AFG had a
variable weak effect (Figure 1d and Additional file 1).
Thus, the gain of function phenotype seen with P864L,
S943F, and F979Z cannot simply be due to disruption of
the critical PEHE domain or loss of the fly-specific Cter
domain, but instead must alter the activity in some dis-
tinctive way. The phenotype and sequences of modifiers
suggests that they produce stable MSL1 proteins. West-
ern blot analysis showed this was the case (Figure 2d).
Mutant MSL1 can be detected in all samples although
K1009X and AFG accumulate to only low levels.
Complementation between msl1 alleles
Li and coworkers [24] have presented evidence that
MSL1 forms homodimers through a sequence at the
extreme N-terminus of the protein. The dominant behav-
iour of the new modifier mutations might be explained if
modifier MSL1 subunits dimerised in vivo with wild-type
polypeptides made from the other allele. We crossed the
three modifier alleles to each other, AFG, K1009X, and
the msl1L60 deletion in all possible combinations (Figure
3a). The two missense modifiers are male lethal over a
deletion, but produced adult males when homozygous.
Thus, these are the first hypomorphic alleles of msl1
reported, and demonstrate how exquisitely sensitive flies
are to the level of MSL1 activity. Changing the MSLMOD
dose by only twofold causes an approximately 100-foldPrabhakaran and Kelley BMC Biology 2010, 8:80
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change in male viability normalised to sisters of the same
genotype (Figure 3b). All classes of surviving adult males
had solid red eye colour (Figure 1d) except rare mod/Df
escapers that had pale mosaic eyes (data not shown). In
addition to strong dose sensitivity, we observed interal-
lelic rescue that is difficult to attribute solely to protein
levels. For instance, heterozygous S943F/AFG male via-
bility was higher than either homozygote (51% vs 35%
and 0%) despite the fact that the AFG protein accumu-
lates to low levels (Figure 2d, lane 7). We can exclude any
viability effects caused by secondary mutations along the
EMS-treated chromosome, because we measure male
viability relative to their homozygous sisters who share
any background mutations. Even though some heteroal-
lelic combinations, such as S943F/P864L, produced males
in nearly Medelian ratios, they had shorter lifespans com-
pared to all other siblings (Figure 3c).
Both K1009X and AFG were scored as nulls when ini-
tially isolated, but their ability to complement P864L and
S943F  m o d i f i e r  a l l e l e s  d e m o n s t r a t e s  t h a t  t h e y  r e t a i n  a
Figure 2 Male Specific Lethal (MSL)1 modifier mutants map to 
the conserved C-terminal PEHE domain. (a) MSL subunit interac-
tions found in previous biochemical and genetic analysis 
[5,23,25,51,55-57]. CC = coiled coil; HAT = histone acetyltransferase; Zn 
= Zn finger. Much of the MSL1 sequence is poorly conserved between 
Drosophila species (thin line). MSL1 is portrayed forming dimers at its 
N-terminus [24]. The chromodomain (CD) of MSL3 has been postulat-
ed to bind RNA [58], but here is depicted as binding histone H3 K36me 
[52,53]. Interactions between RNA and MSL proteins are reported in 
[26-29,31,58]. (b) The sequence alignment presented in Additional file 
2 is illustrated graphically. First bar = 12 Drosophila. Second bar = three 
mosquitoes. Third bar = five non-dipteran insects. Fourth bar = 10 ver-
tebrates. When other species share similarity to vertebrates (blue) they 
are also coloured blue or hatched blue for weak similarity. Open boxes 
= dissimilar sequences. Three regions are strongly conserved within 
Drosophila, but not found in any other group: a highly acidic region be-
fore the PEHE (green), PEHE core domain (yellow), and Cter (orange). 
Locations of the three modifier alleles (red) and two non-modifier al-
leles (white) are shown above. The lower labels show the four trypto-
phan residues and the AFG triplet that serve as sequence landmarks. 
The PEHE domain (Marin [50]) is shown below. (c) Morales et al. [25] 
showed MSL1 fragment E was sufficient to bind MOF ('males absent on 
first') and fragment F could bind MSL3. We found additional MSL3 con-
tacts occur upstream of codon 979 including the AFG triplet (hatched 
box). (d) Anti-MSL1 western blot. Lane 1, wild-type (wt) male; 2, wt fe-
male; 3, msl1P864L male; 4, msl1S943F male; lanes 5-9, females expressing 
ectopic MSL2. Females make less MSL1 protein than males [46]; 5, 
msl1F979Z; 6, msl1K1009X; 7, msl1AFG; 8, msl1L60; 9, msl1L60/CyO. Loading 
control, β-actin.
Figure 3 Interallelic complementation of modifier msl1 muta-
tions. (a) The percentage male viability is shown for each allelic com-
bination. The msl1 allele donated by one parent is on the Y axis and the 
allele donated by the other parent is on the X axis. The Df allele is 
msl1L60. The number in parentheses is the number of msl1a/msl1b 
daughters recovered in each cross. The thicker bars indicate the mod-
ifier alleles recovered in the mosaic eye screen. The P864L/S943F 
heterozygotes used in the longevity assay are boxed. The rare msl1/Df 
male escapers eclosed late, had held out wings, and pale mosaic eyes. 
(b) The viability for all combinations of S943F males are shown with the 
second allele indicated by the right axis. (c) The longevity of the four 
classes of progeny recovered from a cross between msl1P864L/CyO and 
msl1S943F/CyO parents. Although msl1P864L/msl1S943F males and females 
were initially recovered in nearly equal numbers, the adult males ap-
peared weaker, held out their wings, and had shorter lifespans. The 
starting populations were > 150 adults per genotypic class.
(c)
(a) (b)Prabhakaran and Kelley BMC Biology 2010, 8:80
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subset of functions. In contrast, the P864L and S943F
proteins only supported about 7% viability in combina-
tion with frameshift modifier, F979Z. This protein is the
same length as K1009X but has lost the last few amino
acid residues of the PEHE motif followed by scrambled
sequence, whereas K1009X carries a wild-type PEHE
domain (Figure 2b and Additional file 2). We attribute the
greater ability to complement to the presence of a com-
plete PEHE domain in K1009X. These examples of inter-
allelic complementation are most easily accommodated
in a model where MSL1 forms dimers within the MSL
complex [24]. We saw no complementation between
F979Z and K1009X, both of which lack the Cter sequence
immediately following PEHE (Figures 2b and 3a).
Localisation of modifier MSL1 proteins on polytene 
chromosomes
The pattern of complementation suggested that some
mutations might have defects in different functional
domains in the protein. To test this idea we first exam-
ined whether the mutant MSL1 proteins retained any
ability to bind the male X chromosome in the absence of
wild-type MSL1. The F979Z frameshift protein bound
the X at only about 30-50 bands (Figure 4b). Both P864L/
Df and S943F/Df males showed strong painting of the
male X despite the fact that these males die before adult-
hood (Figure 4c, d). The non-modifier AFG and K1009X
proteins bound the X very weakly at only approximately
10-25 bands (Figure 4e, f), which could be partially attrib-
uted to the lower stability of these proteins (Figure 2d).
We next measured the ability of the mutant MSL1 pro-
teins to recruit the other components of the complex. We
found that the MSL2 banding pattern closely resembled
the MSL1 pattern in all mutants (data not shown). Both
P864L and S943F showed reductions in MSL3 and MOF
staining to differing degrees, as might be expected if the
amino acid substitutions altered the docking sites for
these two subunits (Figure 4c,d). F979Z recruited MOF
to the few bands on the X, but no MSL3 was detectable
(Figure 4b). The AFG protein weakly recruited MOF, but
MSL3 was undetectable even in grossly overexposed pho-
tographs (Figure 4f). We also measured roX1 RNA levels
in these flies. Northern blots showed that the F979Z,
K1009X and AFG mutants that fail to recruit MSL3 also
had no roX1 RNA. By contrast the two missense alleles
that painted the X in a nearly normal pattern and could
recruit some MSL3 accumulated high levels of roX1
(Additional file 3).
Subunit interactions
Polytene chromosome analysis only detects subunit
interactions within complexes that were successfully
recruited to the X, but any soluble MSL proteins are lost.
We used coimmunoprecipitation experiments to test the
ability of mutant MSL1 proteins to bind MOF and MSL3
regardless of whether they also bound the X. FLAG-
tagged MSL1 fragments encompassing residues 751-
1,039 were coexpressed in S2 cells with either full length
MSL3 or full length MOF each tagged with haemaggluti-
nin (HA) (Figure 5 and summarised in Additional file 4).
All five MSL1 mutant proteins readily interacted with
both MSL3 and MOF, although the missense mutants
S943F and P864L were slightly stronger and AFG showed
somewhat reduced binding to MSL3. The ability of most
MSL1 mutants to bind both MSL3 and MOF was unex-
pected given the results with polytene chromosomes. In
particular, the two C-terminal truncations, K1009X and
F979Z, each bound MOF weakly and MSL3 not at all on
the polytene chromosomes (Figure 4), but precipitated
MSL3 and MOF efficiently from S2 cells (Figure 5, lanes 9
and 10). This indicates that the PEHE domain is sufficient
for MSL3 interaction in solution, but that the Cter
domain is essential to stably tether MSL3 to the X chro-
mosome. Previous work reported that the Cter rather
than the PEHE domain was sufficient for strong MSL1-
MSL3 binding (Morales et al. [25]). We agree that critical
MSL1-MSL3 interactions map to the Cter, but consider
Figure 4 Modifier msl1 mutations have reduced ability to recruit 
MOF ('males absent on first') and Male Specific Lethal (MSL)3 to 
the X chromosome in vivo. Polytene chromosomes from larvae of the 
genotype given on the left were treated with antibodies recognising 
the MSL subunits shown across the top. In all cases blue is DNA and red 
is the MSL staining. In cases where no MSL binding is evident, an arrow 
indicates the unstained X chromosome. (a)-(d) are males, (e) and (f) 
are female larvae expressing MSL2.Prabhakaran and Kelley BMC Biology 2010, 8:80
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the newly observed PEHE-MSL3 interactions to be
authentic for three reasons. First, they were obtained
after 1 M NaCl washes. Second, an unrelated FLAG-
tagged protein (Figure 5, low molecular weight (LMW)
lane 2) was unable to precipitate either MOF or MSL3.
Finally, we assayed a truncation encompassing MSL1 res-
idues 766-939, L940X, equivalent to fragment F assayed
by Morales et al. [25]. L940X precipitated MOF but not
MSL3 as described earlier (Morales et al. [25] and Figure
5 lane 12) demonstrating that our assay conditions are
comparable to those used by others. These observations
argue against non-physiological binding between MSL3
and K1009X or F979Z due to over expression in cell cul-
ture, and instead, suggest that MSL1 binds MSL3 by two
distinct domains (Additional file 4).
MSL1 mutants abolish MSL complex cis spreading
When MSL complex contains RNA derived from an auto-
somal roX1 transgene, it can either diffuse to the X in
trans, or spread in cis around the transgene. This choice is
strongly affected by the amount of MSL subunits avail-
able for assembly, the rate of roX1 transcription, and the
presence of any other source of competing roX  tran-
scripts [30,32]. We tested whether the red eye phenotype
seen in our MSL1 modifier mutants was due to enhanced
cis spreading from roX1 transgenes, as observed in roX1
roX2  mutants (Figure 1a). No local autosomal MSL
spreading was seen in roX1-  roX2+/Y; F979Z/+ males
regardless whether the GMroX1-75C transgene was hem-
izygous or homozygous (Figure 6b,c). Only a single MSL1
band at the 75C insertion site was detectable, and this is
due to binding to a well characterised internal enhancer
element [48]. The other two modifier alleles did not sup-
port widespread spreading either (data not shown). This
shows that the red eye colour phenotype of modifier
MSL1 mutants is not the result of enhanced long distance
MSL spreading around the GMroX1 transgene.
We next examined the MSL complex distribution in
males whose only source of roX RNA was the GMroX1-
75C transgene. While robust autosomal MSL spreading
(> 1 Mbp) consistently occurred around the GMroX1-75C
transgene in nearly all nuclei of msl1+ homozygotes (Fig-
ure 6d), spreading was abolished in males heterozygous
for any of the five msl1  mutations or deletion (Figure
6e,f). Not only do the modifiers not enhance local spread-
ing, instead they totally block spreading even under con-
ditions where it is normally favoured. We went on to test
Figure 6 Mutations in msl1 abolish local Male Specific Lethal 
(MSL) spreading. In all cases except (c), polytene chromosomes were 
taken from males carrying one copy of GMroX1-75C inserted on the 
third chromosome (arrow). In (c) the transgene is homozygous. Chro-
mosomes were stained with anti-MSL1 antibodies (red). In (a)-(c) the X 
chromosome is roX1ex6 roX2+. (a) msl1+/msl1+, (b) and (c) msl1F979Z/
msl1+. In (d)-(i) the X chromosome is roX1ex6 roX252. (d) msl1+/msl1+ the 
MSL complex covers 73A-77C, (e) msl1+/msl1L60, (f) msl1+/msl1K1009X, 
(g) msl1+/msl1F979Z, P864L, AFG and K1009X also fail to support local 
MSL spreading (not shown), (h) mle+/mlenull, the mleI926Z allele was also 
examined and gave identical results (not shown), (i) msl2+/msl2null. 
Dense MSL1 staining occurs over the X chromosome.
Figure 5 Mutant Male Specific Lethal (MSL) proteins retain MSL3 
and MOF ('males absent on first') binding in vitro. FLAG-tagged 
MSL1 protein (residues 751-1,039) and either full-length haemaggluti-
nin (HA)-MOF, HA-MSL3, or both were coexpressed in Drosophila S2 
cells, bound to beads coated with anti-FLAG antibodies, and pelleted. 
The recovered proteins were visualised with anti-HA antibodies. MSL1 
inputs: lane 1, no FLAG plasmid; 2, empty FLAG vector; 3, unrelated 
FLAG protein of 70 kDa (low molecular weight (LMW)); 4-6, wild-type 
MSL1; 7, P864L; 8, S943F; 9 F979Z; 10, K1009X; 11, AFG; 12, L940X trun-
cation similar to fragment E in [25]. Bottom: the membrane was 
stripped and reprobed with antibodies recognising FLAG to visualise 
the MSL1 proteins. The different sizes reflect different truncations. The 
unrelated FLAG-tagged protein in lane 2 is much larger than the MSL1 
fragments, but was repositioned for comparison.Prabhakaran and Kelley BMC Biology 2010, 8:80
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whether mutations in any MSL subunit would likewise
dominantly abolish local spreading. We found that msl21/
+, mle1/+ and mleI926Z/+ heterozygous males continued to
support massive cis spreading from GMroX1-75C (Figure
6h,i). This indicates that cis  spreading is particularly
dependent upon MSL1.
Modifier MSL1 proteins support dosage compensation 
using autosomal roX1 RNA
Finding that msl1 mutations abolished cis spreading of
mature MSL complexes around autosomal roX1  trans-
genes despite the presence of wild-type MSL1 subunits,
we asked if these same flies had impaired ability to dosage
compensate the X chromosome in trans. We measured
the ability of the different msl1 mutants to support dos-
age compensation when the only source of roX RNA was
the autosomal transgene. Males that lack the endogenous
roX1 and roX2 genes die, but can be partially rescued by
an autosomal GMroX1 transgenes [32,49]. Northern blots
showed that roX1 RNA levels produced by GMroX1-75C
are comparable to wild-type levels (data not shown). We
found that an autosomal GMroX1 transgene could not
restore male viability if the amount of MSL1 was reduced
by half in msl1L60/+ hemizygous males (Table 1). This
assay clearly divided the msl1 point mutants into distinct
classes. The three modifier alleles that enhance eye pig-
mentation in GMroX1-75C mosaic males restored male
viability when heterozygous with one copy of msl1+
(Table 1). The AFG  and  K1009X  non-modifier alleles
behaved more like simple loss of function L60 deletion in
this assay. The ability of the modifier alleles to restore
dosage compensation to the X nearly as well as wild-type
MSL1 demonstrates that such complexes have essentially
normal chromatin remodelling activity, despite having
dramatically impaired ability to spread locally.
Modifier mutation in the MLE RNA helicase
The weakest modifier recovered in our screen was a late
frameshift mutation in the MLE RNA helicase subunit of
the MSL complex (Figure 7a, b). As was the case with
msl1, null mutations in mle do not act as modifiers (data
not shown). The mleI926Z allele displays a male-specific
lethal phenotype when homozygous or in combination
with null alleles of mle. This mutation does not affect
long distance MSL spreading from sites of roX1  tran-
scription (data not shown). Because the mutant protein
retains the two N-terminal double stranded (ds)RNA
binding motifs and helicase region, we asked if the reces-
sive male lethality might be due to loss of the distinct gly-
cine-aromatic heptad repeats at the C-terminus of MLE,
postulated to bind RNA [27]. We constructed an mle
transgene lacking the repeats (Figure 7a) but found that it
supported male viability (Figure 7c), but the rescued
males were sterile. This shows that the heptad repeat is
needed for its germline function, but not for dosage com-
pensation. Thus, male lethality displayed by the modifier
allele is most likely due to the loss of some element
required for dosage compensation located between
codons 925 and 1,200.
Discussion
Genetic screens assaying for male-specific lethality iden-
tified the known components of the dosage compensa-
tion complex, and yet the precise mechanism by which
t h e  M S L  c o m p l e x  a c t s  u p o n  R N A  p o l y m e r a s e  i s  n o t
understood. We developed a new approach to search for
factors that are needed for either the activity or targeting
of the MSL complex using a simple eye pigmentation
assay. This dominant screen has the potential to recover
genes that would have been overlooked previously
because they perform additional essential functions in
females. In fact, two of the new mutants are recessive
lethal to females as well as males. Based on the following
criteria we consider the mutants isolated by this strategy
relevant to the process of dosage compensation. (1) All
modifiers alter eye pigmentation exclusively in males. (2)
The modifiers have no effect on general position effect
variegation. (3) The modifiers act on roX1  transgene
inserted in diverse repressive environments indicating
Table 1: Modifier alleles of msl1 retain much of their 
activity
msl1 allele msl1/+ male viability (%) N







The viability of roX1 roX2/Y; msl1/+; [w+ GMroX1-75C]/+ males was 
measured when the only source of roX RNA was the autosomal 
transgene. In each case the progeny were from roX1 roX2 mothers 
mated to roX+/Y; msl1/CyO; [w+ GMroX1-75C]/[w+ GMroX1-75C] 
fathers. The CyO progeny were discarded and the fraction of msl1/
+ sons and daughters was compared. The first column indicates 
which msl1 allele was used. The middle column shows the 
percentage male viability compared to their sisters, and the right 
column gives the number of msl1/+ females recovered in each 
cross.Prabhakaran and Kelley BMC Biology 2010, 8:80
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that they act on roX1  rather than relieving flanking
repressive chromatin. (4) Of the 13 mutants recovered, 4
mapped to genes encoding known components of MSL
dosage compensation complex. Here we focused on the
unusual characteristics of the new msl1  mutations
because their eye colour phenotype indicates increased
dosage compensation, yet in most assays they behave as
loss of function.
A chromatin-remodelling machine similar to the MSL
complex can be found in most animals where it probably
acetylates histone H4 at many genes in both sexes. Within
the genus Drosophila this complex has been recruited to
X-linked genes in males to carry out dosage compensa-
tion. This specialisation almost certainly required
changes in one or more of the MSL subunits allowing
them to interact with roX RNAs and bind only the male
X. The most conserved region of MSL1 proteins from
insects to vertebrates is termed the PEHE motif [50]. The
PEHE domain was known to bind the MOF histone
acetyltransferase [23,25]. A short interval in the middle of
the PEHE, which we term the Core (yellow box in Figure
2b and Additional file 2), is strongly conserved among
most insects and vertebrates, but is significantly different
in  Drosophila. Immediately upstream of the PEHE
domain is a highly acidic region and downstream is a sec-
ond strongly conserved block, Cter, found only within the
genus Drosophila (Figure 2b). The acidic motif, Core, and
Cter Drosophila-specific domains are candidate adapta-
tions needed for MSL complex to carry out the new role
of dosage compensation. Our mutational analysis high-
lights the roles of PEHE and Cter.
The three modifier mutations recovered in msl1 cluster
around the PEHE domain. The two missense mutants
display an unusual constellation of phenotypes. When
heterozygous with a wild-type allele, the males are fully
viable showing that the X is compensated, but more
importantly, the eye colour shifts from mosaic to solid
red. This shows that MSL complexes containing the
mutant protein are more effective at modifying chroma-
tin immediately around sites of roX1 transcription so that
the adjacent miniwhite marker has a high probability of
being epigenetically activated. The same mutations are
male specific lethal over a deletion indicating loss of func-
tion. While these proteins paint the X in a nearly normal
pattern, they can only partially recruit MOF and MSL3 to
the X. MSL complexes lacking MSL3 are restricted to
approximately 35 high affinity sites along the X [51], so
finding a high density of MSL1 bands in the modifiers
suggests that MSL3 likely associates transiently with
mutant MSL1 at all sites in vivo even if it is difficult to
capture with our fixation conditions. This is in agreement
with our finding that the modifier MSL1 mutants bind
MSL3 efficiently in precipitation assays (Figure 5).
The Cter domain (residues 994-1,039) is strongly con-
served within the genus but shows no resemblance to the
C-terminus in mosquitoes or other insects (Additional
file 2). This domain is essential for dosage compensation
in vivo as shown by the male-specific lethal phenotype of
the late nonsense mutant K1009X. The initial mapping of
MSL1-MSL3 interactions to the Cter domain [25] was
surprising because this domain is not conserved outside
Drosophila, and yet MSL1 binds MSL3 even in verte-
br a t es.  H e r e  w e  r esolve  t his iss ue  b y s ho wi ng t ha t t he
conserved PEHE domain carries a second MSL3 binding
region. While our observations that K1009X and F979Z
fail to recruit MSL3 to polytene chromosomes is fully in
agreement with earlier work, we were initially surprised
to find both truncations robustly precipitated MSL3 in
coimmunoprecipitation experiments in cell culture. The
ability of K1009X and F979Z to bind MSL3 maps to the
second half of the PEHE domain (Figure 2c). This is con-
sistent with the observation that mutations in the highly
conserved AFG residues within the PEHE domain abolish
MSL3 binding in vivo despite the presence of the Cter
domain. This argues that the PEHE domain makes critical
contacts with both MSL3 and MOF that are likely to be
evolutionarily ancient because only the PEHE domain is
conserved through vertebrates. The new mosaic eye assay
used in this screen apparently selected for mutants that
subtly altered subunit interactions without completely
abolishing them. We propose that the Cter motif exclu-
Figure 7 A late truncation in MLE (for 'maleless', RNA helicase) 
produces a modifier phenotype. (a) The MLE protein contains two 
double stranded RNA binding motifs at the N-terminus and a large he-
licase domain in the middle. The C-terminus has 12 imperfect copies of 
a glycine-rich heptad repeat, each of which has 1 aromatic residue. The 
modifier allele has a 1-bp deletion in the I926 codon. The MLE21Δgly 
transgene carries a deletion of the heptad repeats on a genomic clone 
expressed from its native promoter. (b) Male and female homozygous 
for [w+ GMroX1-75C] who are either mle+/CyO (top) or mleI926Z/CyO 
(bottom). (c) The MLE21Δgly transgene rescues male viability, but not 
fertility. y w; mle1/CyO y+; [w+ MLE21Δgly]/+ males and females were 
mated and the homozygous mle1/mle1 progeny were counted and 
scored for eye colour and sex. The MLE21Δgly construct could not be 
assayed for its effect on mosaic eyes of GMroX1-75C because of the 
linked w+ marker.Prabhakaran and Kelley BMC Biology 2010, 8:80
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sive to Drosophila provides additional contacts necessary
for the recently acquired function of dosage compensa-
tion. We note that removing this C-terminal domain
results in loss of roX1 RNA (Additional file 3) as expected
if this motif plays some new role in aiding MSL3 target
the X in conjunction with roX RNAs.
We propose that the PEHE and Cter domains have dis-
tinct functions based on the observation that the mis-
sense modifier mutants restore partial male viability to
K1009X and AFG mutants, but not to an msl1 deletion. If
each mutant affected distinct functions within MSL1,
then males making mixed MSL complexes might partially
restore function. However, the F979Z modifier only
weakly complements P864L and S943F. Although both
F979Z and K1009X delete the Cter domain, F979Z also
deletes the last few conserved residues of the PEHE
domain explaining the reduced ability to complement.
This would also explain why F979Z fails to complement
AFG. These complex complementation patterns are most
easily explained if MSL1 dimerises within MSL com-
plexes [24].
Prior to this study, the only factor affecting the mosaic
miniwhite  expression linked to roX1  transgenes was
removing the endogenous roX1 and roX2 genes (Park et
al, [32]). This also results in massive local spreading of
the MSL complex around the roX transgene. We were
therefore surprised to find that while the dominant msl1
modifiers have the same affect on the mosaic eye pattern
as roX deletions, the modifiers abolished cis spreading
rather than enhancing it. Massive local spreading appears
to be coupled to cotranscriptional assembly of MSL sub-
units onto nascent roX transcripts [30,31]. Under condi-
tions where assembly is completed by the time the 3' end
of roX1 RNA is released from polymerase, local spreading
is favoured. When partially completed roX transcripts are
released before assembly is completed, the inactive com-
plex diffuses away from the site of roX synthesis prevent-
ing local spreading. The msl1 mutants characterised here
block local spreading in a dominant fashion even when
wild-type subunits are available. We propose this is a
direct reflection of how the mutant MSL1 subunits affect
the assembly process.
Flies are exquisitely sensitive to the dose of MSL1.
When MSL2 is ectopically expressed in females, only
about 15% of the animals reach adulthood and are sterile.
Simply reducing MSL1 by half completely relieves this
toxicity [12]. However, overexpressing MSL1 in the pres-
ence of ectopic MSL2 kills 100% of females [46]. In the
present study we found that the viability of males carry-
ing modifier mutations P864L or S943F changes drasti-
cally over only a twofold change in protein levels. We also
found that reducing the MSL1 dose by half in msl1L60/+
males is sufficient to block distant cis spreading of the
MSL complex. This suggests that the availability of MSL1
subunits is the most limiting factor controlling assembly
onto roX RNAs. Although MSL1-MSL2 heterodimers are
thought to form the core of the dosage compensation
complex, we propose MSL1 has a stronger effect on
assembly kinetics because it alone recruits MSL3 and
MOF to the complex. The modifier alleles isolated here
reinforce this model. In this case they act not by altering
the abundance of MSL1, but rather act at the MSL1:MOF
and MSL1:MSL3 interfaces. The two missense MSL1
modifier proteins are produced in amounts comparable
to wild type (Figure 2d), stabilise roX1 RNA (Additional
file 3), are incorporated into MSL complexes and paint
the X in a nearly normal pattern (Figure 4). Their capacity
to block mixed complexes containing wild-type MSL1
from spreading is more likely due to problems coupling
MSL assembly with 3' processing and release of roX1
transcripts. The red eye phenotype indicates that com-
plexes tend to accumulate immediately around the site of
roX1  transcription, activating miniwhite. The role of
MSL3 in spreading may be its ability to recognise actively
transcribed genes by their histone H3K36me3 mark
[52,53]. This might explain why alterations around the
PEHE domain that affect whether or how MSL3 is pre-
sented to chromatin would inhibit extensive cis spread-
ing.
We also isolated a single modifier allele in mle that is a
late frame shift that retains the two dsRNA binding
motifs and the large helicase domain. As in the case of the
msl1 modifier alleles, the mle modifier displays recessive
male lethality in addition to the dominant effect on
mosaic eye colour. We showed that the male lethality can-
not be attributed to the aromatic repeat sequence at the
C-terminus, but rather must be located more upstream in
a poorly characterised region of the protein. The bio-
chemical role of MLE in dosage compensation is not
known, but it is tempting to speculate that it acts on roX
RNAs, either during assembly of the MSL complex, or to
catalyse conformational changes in the complex either
during cycles of histone modification, or movement
along the chromosome.
Conclusions
We developed a new genetic strategy to identify compo-
nents of the dosage compensation pathway in Drosophila
using a simple dominant eye colour phenotype. This
yielded new mutation of msl1 and mle with novel pheno-
types never observed in previously isolated alleles, which
are likely due to disruption in specific subunit contacts
that alter complex assembly. We also recovered muta-
tions in new genes not previously linked to dosage com-
pensation that have additional functions in females.Prabhakaran and Kelley BMC Biology 2010, 8:80
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Methods
Fly stocks
The  GMroX1-75C  transgenic stock was as previously
described [44]. The roX1 transgenes located at 60F and
58D contain a 1-kb insertion of foreign sequence at the
extreme 3' end between roxbox2 and roxbox3. This inser-
tion lowers, but does not eliminate activity. The msl1
alleles L60, AFG, and K1009X (along with 30 others) were
isolated previously in Mitzi Kuroda's laboratory (Har-
vard-Partners Ctr. for Genetics and Genomics, Harvard
Medical School, 77 Avenue Louis Pasteur, NRB 168, Bos-
ton, MA 02115, USA) during a γ-ray mutagenesis select-
ing for females that could tolerate ectopic MSL2
expression similar to that reported in Lyman et al. [51].
The full genotype of the roX1 rox2 double mutant stock is
y w roX1ex6  Df(1) roX252  nod  [w+cos4Δ] [54]. For eye
colour assays we use a stock containing a w- derivative of
[cos4Δ] located on the second chromosome (a gift from
Victoria Meller, Department of Biological Sciences,
Wayne State University, 5047 Gullen Mall, Detroit, MI
48202, USA).
Mutagenesis
Males isogenic for the second chromosome were fed 25
mM EMS overnight, rested 1 day and then mated to
GMroX1-75C  virgins. The modifier candidate males
recovered initially showed an extremely weak phenotype,
but males in later generations developed a dramatically
darker red eye phenotype after brother-sister matings
resulted in progeny homozygous for the GMroX1-75C
transgene. The design of the screen prevented recovery of
X-linked mutations. Third chromosome mutations were
unlikely to be recovered because we later learned that the
eye phenotype required animals to be homozygous for
the unmutagenised third chromosome carrying
GMroX1-75C. Several stocks initially carried extraneous
secondary recessive lethal mutations that were later
removed by recombination.
Complementation tests
Balanced males from each of the 13 modifier mutants
were mated to w; msl1L60/CyO, w; msl21/CyO, or w; mle1/
CyO  virgins, and the presence or absence of flat wing
males was scored. Interallelic complementation tests
were performed between msl1/CyO mutations carrying
[w+ GMroX1-75C], with partial rescue measured as the
number of adult heteroallelic sons recovered compared to
sisters of the same genotype. Lifespan assays were per-
formed on freshly eclosed adults housed 30 animals of
the same genotype and sex per vial on standard molasses
food without yeast supplement. The survivors were
counted on alternate days and then placed in fresh food
vials.
Sequencing
The genomic DNA from either homozygous or hemizy-
gous adult females was recovered, amplified with sets of
gene-specific primers pairs, and then sequenced from
each end of the fragment. The sequence of each mutation
is given in Additional file 3.
Sequencing primers for msl1  were: primer 1R 5'
GGAGACTCCTTCATGTTGATACC 3'; primer 1L 5'
GAATTATGAGATCGTAGGACCG 3'; primer 2R 5'
CGCTTCTAATGCATCTACCAT 3'; primer 2L 5'
CACACAAACGATAGATGCG 3'; primer 3R 5'
CGTAACCTGTGACGAATGAC 3'; primer 3L 5'
GGAAATCAGAATCGGATAACT 3'; primer 4R 5'
TGAACTGTCACCTCGTTGA 3'; primer 4L 5'
GTCTCAGAGCCCAGATCAAG 3'; primer 5R 5'
GTTAACTCTGGTGCTTTCACGTT 3'; primer 5L 5'
GAAGGAGCAGATACGGCTT 3'.
Primer pairs used to sequence mleI926Z were: mleP1L
5' TTAATCGATATCAGAATAGAC 3'; mleP1R 5'
CATCGTGGTTTAGAGGGCGATAGG 3'; mleP2L 5'
CAGCGGATGCTGGTGCTTCGG 3'; mleP2R
5'GATTTGGCCGTAGGCCATATTC 3'; mleP3L 5'
GACTCCCACGATAGCCCGAGG 3'; mleP3R
5'ATCTCTAAACTGTTTTTTAATAC 3'; mleP4L 5'
TCTGTTATCTCTTACATTCATACCC 3'; mleP4R
5'AGTGTCGCCCAATTGCTCGCACCGC 3'; mleP5L
5' ACCCAGATTGCCCAATACATTCTT 3'; mleP5R
5'AATTGTCGAAGAGTTTCACCCC 3'; mleP6L 5'
GTCATACATTTCTAGTCCTAATTT 3'; mleP6R
5'TTCTGGAACAGGCTCGAAAACCTTGCGT 3';
mleP7L 5' AACCTGATCTTTGCGCTTATGAAGT 3';
mleP7R 5'CCGAGGACCATCATCTTTCCAAGT 3';
mleP8L 5' GGAGCCACCTCCGGTAGACGCAGT 3';
mleP8R 5'CCAAGTTGCTGCAATTCACCGAGG 3';
mleP9L 5' GGGATGACCCCGTGCTGGATGTG 3';
mleP9R 5'ATTATTTCCATATCCTCCTCCA 3';
mleP10L 5' GAATCAGGAATTCTGCCGCACCAATC
3'; mleP10R 5'CACATGCGTATTTAATGCCAAAAA 3'.
Deleting MLE glycine repeat
The region immediately upstream of the glycine repeats
was amplified with MLER1 5' GCAGCGTGAATCAG-
GAATTC  3'; ASCBGL 5' CGCTTTACTAACAG-
CAGCTTGGCGCGCCGTGGAAACGGCAGAT 3'. The
region immediately downstream of the glycine repeats
was amplified with: LGBCSA 5' CGCCGTGGAAACG-
GCAGATCTTTTGGAGGAGGATATGG 3'; BSNOT 5'
GTTACCCCAGCGGCCGCC 3'. The two resulting PCR
fragments were joined by PCR with the two outside prim-
ers MLER1 and BSNOT. This fragment lacking the gly-
cine repeats was substituted for the wild-type sequence in
an MLE21 backbone [27].Prabhakaran and Kelley BMC Biology 2010, 8:80
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Polytene chromosome staining
This was performed as previously described [51].
Northern blots
Total RNA from either sexed adults or wandering third
instar larvae was extracted with Trizol reagent (Invitro-
gen: http://www.invitrogen.com) as directed by the sup-
plier and 10 μg was run on 1.0% agarose in 3-(N-
morpholino)propanesulfonic acid (MOPS) formaldehyde
gels. The RNA was transferred to Hybond N+ mem-
branes in 50 mM NaOH and then hybridised to dsDNA
probes labelled by random priming.
Recombinant DNA
To make the FLAG-tagged MSL1 proteins, genomic DNA
was prepared from homozygous F979Z, K1009X and
AFG females, hemizygous S943F and P864L males and
wild-type males. The last 870 bp of the msl1 gene encoding
amino acids 751-1,039 was amplified using the following
primers: MSL1CTF 5' ACAAGATCTCCACACCAACG
CCTGGCTCA 3'; MSL1CTR 5' CCACTCGAGCTAAC-
GATTCTTCTGGCGCTT 3'.
The primers contained either BglII or XhoI sites (bold).
FLAG MSL1CT constructs were made by digesting the
appropriate PCR fragments by BglII and XhoI, then clon-
ing into BglII XhoI double digested pUAST FLAG vector.
The msl1 L940X mutation was made with the primer 5'
CAAAACTCGAGCTAAGGATCCAGCGCAACCAAC
3' instead of MSL1CTR. The cloning of all constructs was
confirmed by sequencing. The FLAG MSL1CT expres-
sion was driven by cotransfecting pActin:GAL4 plasmid
(a gift from Hugo Bellen, Department of Molecular and
Human Genetics, HHMI, Baylor College of Medicine,
One Baylor Plaza, Houston, TX 77030, USA).
pCasper.HA mof and pCasper.HA msl3 were kind gifts
from Max Scott (Department of Genetics, North Caro-
lina State University, Campus Box 7614, Raleigh, NC
27695-7614, USA) [23]. The HA.mof and HA.msl3
inserts were subcloned into pET28a vector between
EcoRI and SalI sites. pET.HAmof was digested with EcoRI
and  XhoI, the HAmof fragment was gel purified, and
cloned into EcoRI XhoI digested pAC5.1/V5 His-A vector.
pET.HAmsl3 was digested with EcoRI and NotI, the
HAmsl3 insert was gel purified, and cloned into EcoRI
and NotI digested pAc5.1/V5 His-A vector.
Coimmunoprecipitation
S2 cells were plated at a density of 1 × 106 cells/ml in six-
well plates. After 24 h the cells were transfected with 400
ng of total DNA mixture of equal proportions of the
appropriate plasmids using the Effectene transfection
reagent (Qiagen Inc, 27220 Turnberry Lane, Valencia, CA
91355, USA). After 36 h the cells were harvested and
washed twice with ice-cold phosphate-buffered saline
(PBS). Cells were pelleted and resuspended in 200 μl of
lysis buffer (50 mM tris(hydroxymethyl)aminomethane
(Tris)-HCl (pH 8.0), 100 mM NaCl, 1% nonyl phenoxy-
lpolyethoxylethanol (NP40), 10% glycerol, 1.5 mM ethyl-
enediaminetetraacetic acid (EDTA; pH 8.0) and protease
inhibitor (Sigma-Aldrich, Customer Service, PO Box
14508, St. Louis, MO 63178, USA). Lysis was performed
by rotating in lysis buffer at 4°C for 30 min. The lysate was
cleared by spinning at 13,000 rpm at 4°C for 10 min. EZ
view FLAGM2 beads from Sigma were equilibrated in the
lysis buffer and 30 μl of 50% bead slurry was used for each
precipitation. A total of 180 μl of the lysate and 30 μl of
the 50% bead slurry was rotated overnight at 4°C. The
beads were pelleted by spinning at 2,500 rpm for 30 s and
washed thrice with washing buffer (50 mM Tris-HCl (pH
8.0), 1 M NaCl, 1% NP40, 10% glycerol, 1.5 mM EDTA
(pH 8.0) and protease inhibitor (Sigma)). After a final
wash in low salt (150 mM) buffer, the beads were sus-
pended in 20 μl of low salt wash buffer and SDS loading
dye.
Western blots
The entire sample was boiled with SDS loading dye for 3
min and loaded onto an 8% SDS-polyacrylamide gel. Pro-
teins were transferred in Tris-glycine buffer (pH 8.3) con-
taining 25 mM Tris and 192 mM glycine and 20%
methanol, for 1.5 h at 400 mA. Membranes were incu-
bated with anti-HA antibody (Covance Research Prod-
ucts, Inc., 5858 Horton Street, Suite 500, Emeryville, CA
94608, USA) overnight at 4°C. After three 15-min washes
in PBS-Tween and 2 h incubation at room temperature
with anti-mouse horseradish peroxidase conjugate anti-
body (Jackson ImmunoResearch Laborotories, Inc., PO
Box 9, 872 West Baltimore Pike, West Grove, PA, 19390,
USA), the proteins were detected with luminol system
(Santa Cruz Biotechnology, Inc., 2145 Delaware Avenue,
Santa Cruz, CA 95060, USA).
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